Primary peritoneal cancer Trials in Leuven, Belgium
Conditions / Primary peritoneal cancer / Leuven, Belgium
Clinical trials for Primary peritoneal cancer investigate a range of treatment strategies and patient populations.
11 total trials for this combination
Showing top 10 of 11 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT00989131 | Study of Paclitaxel in Patients With Ovarian Cancer | COMPLETED | PHASE3 |
| NCT01281254 | AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2) | TERMINATED | PHASE3 |
| NCT01253681 | Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian Cancer | COMPLETED | PHASE1 |
| NCT04590326 | A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab | RECRUITING | PHASE1/PHASE2 |
| NCT05456685 | Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer | ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT06824467 | A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) | RECRUITING | — |
| NCT02606305 | Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer | COMPLETED | PHASE1/PHASE2 |
| NCT01663857 | A Study LY2228820 for Recurrent Ovarian Cancer | COMPLETED | PHASE1/PHASE2 |
| NCT01204749 | TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer | COMPLETED | PHASE3 |
| NCT02012192 | GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer | TERMINATED | PHASE1/PHASE2 |